There are over 25 technology platforms available for use in therapy development efforts.
In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The concept of targeted protein degradation presentsrevolutionary drug development opportunities and is anticipated to bring abouta paradigm shift in modern healthcare. The first targetedprotein degrader, called proteolysis targeting chimera (PROTAC), was developedabout a decade ago. Presently, a variety of other such chemical entities andmolecular glues are under investigation. In fact, certain pipeline candidates arealready in the mid to late-phase trials and are anticipated to soon enter themarket.


To order this 330+page report, which features 130+ figures and 145+ tables, please visit this -


The USD 3.6 billion (by 2030) financial opportunitywithin the target protein degradation market has been analyzed across thefollowing segments:

§  Typeof payment of licensing agreements

§  Upfrontpayments

§  Milestonepayments


§ Type of protein degrader

§  Degronimids



§  SpecificBET and DUB inhibitors

§  Otherprotein degraders


§ Therapeutic area

§  Neurodegenerativedisorders

§  Oncologicaldisorders

§  Othertherapeutic areas


§  Routeof administration  

§  Oral

§  Intravenous

§  Otherroutes


§  Keygeographical region

§  NorthAmerica

§  Europe

§  Asia-Pacific


The Targeted Protein Degradation Market: Focus on Therapeuticsand Technology Platforms (based on Degronimids, ENDTACs, EpichaperomeInhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs,Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUBInhibitors), 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:

§  Arvinas

§  CaptorTherapeutics

§  Celgene

§  Genetech

§  KymeraTherapeutics

§  MissionTherapeutics

§  Progenra

§  RadiusHealth 

§  SanofiGenzyme

§  Zenopharm


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Profiles

6. Clinical Trial Analysis 

7. KOL Analysis

8. Publication Analysis

9. Funding and Investment Analysis

10. Partnerships and Collaborations

11.  MarketSizing and Opportunity Analysis

12. Executive Insights


13. Concluding Remarks


14. Appendix 1: Tabulated Data


15. Appendix 2: List of Companies andOrganizations


To purchase a copy, please visit


You may also beinterested in the following titles:

1.  DNA-EncodedLibraries: Platforms and Services Market

2.  GlobalStem Cells Market: Focus on Clinical Therapies, 2020–2030

3.  TheHuman Microbiome Market: Focus on Therapeutics (including gut-brain axistargeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition),2019-2030


About Roots Analysis

Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at


Contact Information

RootsAnalysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Facebook -

LinkedIn -

Twitter -